# FDA Inspection 1092617 - Carter BloodCare - May 23, 2019

Source: https://www.keypedia.com/records/fda_inspections/carter-bloodcare/3ebea958-1b37-4e58-845e-2966096af75a
Source feed: FDA_Inspections

> FDA Inspection 1092617 for Carter BloodCare on May 23, 2019. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1092617
- Company Name: Carter BloodCare
- Inspection Date: 2019-05-23
- Classification: No Action Indicated (NAI)
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1023814 - 2017-08-25](https://www.keypedia.com/records/fda_inspections/carter-bloodcare/7c649d44-390b-4689-b634-469600b3fd89)
- [FDA Inspection 938894 - 2015-07-10](https://www.keypedia.com/records/fda_inspections/carter-bloodcare/f0edfa19-f88b-43fa-80ce-e914698e9ba2)
- [FDA Inspection 818232 - 2013-02-13](https://www.keypedia.com/records/fda_inspections/carter-bloodcare/f22fd6c5-e68a-4d32-a968-af550430f9dc)
- [FDA Inspection 706855 - 2011-01-13](https://www.keypedia.com/records/fda_inspections/carter-bloodcare/7e265aff-ae50-4c81-bf58-54520f16de84)

Company: https://www.keypedia.com/companies/carter-bloodcare/9ad4f15c-23c0-41af-a70c-ef89efa313a8

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d